Charles River Completes NewLab Acquisition

Charles River Laboratories has completed the acquisition of privately held NewLab BioQuality AG, a Dusseldorf, Germany-based provider of safety and quality control services to biopharmaceutical clients. NewLab joins Charles River Biopharmaceutical Services, which provides services to support the development and manufacture of biologics.
   
James C. Foster, chairman, president and chief executive officer of Charles River, said, “The acquisition of NewLab further strengthens our portfolio of essential products and services to help our clients accelerate drug development. NewLab enhances the scientific depth, geographic scope and client base of Charles River’s global biopharmaceutical services offering to support the rapidly growing market for biologic drug compounds. We are pleased to welcome NewLab BioQuality to the Charles River family.”